Paradigm Biopharmaceuticals (PBIGF, $0.26) was a top loser over the last three months, falling to $0.26 per share. A.I.dvisor analyzed 840 stocks in the Biotechnology Industry for the 3-month period ending May 16, 2025, and found that of them (2) exhibited an Uptrend while of them (7) demonstrated a Downtrend.